The Potential CV Impact of Triglyceride Level Reduction

When used together, sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were able to lower the risk of major adverse cardiovascular events and kidney disease by 11% and 33%, respectively.

Individuals who ate diets that aligned closer to DASH and Mediterranean guidelines had lower levels of plasminogen activator inhibitor-1 and homocysteine biomarkers.

In 2 abstracts presented at ASCO 2024, researchers addressed the use of GLP-1s for weight loss and to reduce cardiovascular outcomes in women with breast cancer.

In a session presented at the 2024 Heart in Diabetes Conference, Neha Pagidipati, MD, MPH, discussed weight change and its effects on cardiovascular complications.

In abstracts presented at the 2024 American Society of Clinical Oncology’s annual meeting, researchers addressed the association between heart failure and multiple types of cancers.

While elevated BMI at baseline was not associated with increased cardiovascular risk, cumulative excess BMI was associated with an increased risk in people under 50.